News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nanobac Pharmaceuticals, Inc. Acquires Option to License Calgenex Corporation Technology to Treat Atherosclerosis and Prostatitis



10/3/2007 8:48:27 AM

TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") announced today that it signed an agreement with Calgenex granting Nanobac an option to assess Calgenex’ drug delivery technology for potential use with Nanobac’s drug combinations used in treating atherosclerosis, prostatitis, and other pathologic calcification diseases. The technology includes a novel combination of bisphosphonate and silicic acid.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES